Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hunan Province Tumor Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1)≥18，advanced non-small cell lung cancer confirmed by histopathology, and were previously or currently treated with gefitinib tablets (as the first-line treatment) or osimertinib (first-generation TKI resistance treatment) or crizotinib capsules monotherapy were evaluated for efficacy.
2\) Able to provide FFPE samples with a storage life of 5 years: Large specimen 5 pieces in each case; 10 puncture specimens in each case
You may not be if
1\) Pathological evaluation of the tissue sample has too few tumor cells (total number of tumor cells \>20%);
2\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs;
3\) Maintenance treatment when the disease does not progress after other anti-tumor treatments.
